Bayer, which recently introduced a new operating model, has entered a strategic collaboration with Aignostics, a spin-off from Charité-Universitätsmedizin Berlin, focused on artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development.   The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s expertise in discovering and developing no...